




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 471/04, A61K 31/47 // (C07D 471/04, 235/00, 221/00)		A1	(11) International Publication Number: WO 92/06093 (43) International Publication Date: 16 April 1992 (16.04.92)
(21) International Application Number: PCT/US91/06682			(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), LU (European patent), NL (European patent), SE (European patent).
(22) International Filing Date: 13 September 1991 (13.09.91)			
(30) Priority data: 593,078 5 October 1990 (05.10.90) US			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: MINNESOTA MINING AND MANUFACTURING COMPANY [US/US]; 3M Center, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).			
(72) Inventor: GERSTER, John, F. ; Post Office Box 33427, Saint Paul, MN 55133-3427 (US).			
(74) Agents: REEDICH, Douglas, E. et al.; Minnesota Mining and Manufacturing Company, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).			

(54) Title: PROCESS FOR THE PREPARATION OF IMIDAZO[4,5-C]QUINOLIN-4-AMINES



(57) Abstract

A process is disclosed for preparing 1-substituted-1H-imidazo[4,5-c]quinolin-4-amines of formula (I). The process involves reacting a 1-substituted-1H-imidazo[4,5-c]quinoline-5-oxide with an acylating agent and reacting the product thereof with an aminating agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

PROCESS FOR THE PREPARATION
OF IMIDAZO [4,5-C] QUINOLIN-4-AMINES

BACKGROUND OF THE INVENTION

5

Field of the Invention

This invention relates to processes for preparing 1H-imidazo[4,5-c]quinolines. In another aspect this invention relates to processes for preparing 10 1-substituted-1H-imidazo[4,5-c]quinolin-4-amines.

Description of the Related Art

The synthesis of 1H-imidazo[4,5-c]quinolin-4-amines has been described in U.S. Pat. Nos. 4,689,338 15 (Gerster) and 4,929,624 (Gerster et al.). The methods described therein involve the step of heating the 4-chloro compound in the presence of ammonium hydroxide or ammonia under pressure (e.g., in a sealed reactor) to afford the 4-amino compound.


20 Khim. Geterosiklicheskikh Soedinenii 1976, 2, 229 (Solekhova et al.) describes the amination of pyridine N-oxide and quinoline N-oxide at the 2-position with ammonia and some ammonia salts in the presence of p-toluenesulfonyl chloride. Similarly, Chem. Pharm. Bull. 25 (Tokyo) 1984, 1, 35 (Hamana et al.) describes the reaction between quinoline 1-oxide and various amines in the presence of an acylating agent.

SUMMARY OF THE INVENTION

30

This invention provides a process for preparing a compound of Formula I

5



10 wherein

R₁ is straight chain or branched chain alkyl of one to about 10 carbon atoms; straight chain or branched chain alkenyl of 3 to about 10 carbon atoms wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen; substituted straight chain or branched chain alkenyl of 3 to about 10 carbon atoms wherein the olefinic unsaturation is at least one carbon atom removed from the 1-nitrogen, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, and cycloalkyl of 3 to about 6 carbon atoms substituted by lower alkyl; and substituted straight chain or branched chain alkyl of one to about 10 carbon atoms, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, and cycloalkyl of 3 to about 6 carbon atoms substituted by lower alkyl;

R₂ is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms; benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms;


each R is independently selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is an integer from zero to 2, with the proviso that if n is

2, then said R groups together contain no more than 6 carbon atoms; or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of:

5

(i) providing a compound of Formula II

10



15

wherein R, n, R₁, and R₂ are as defined above;

(ii) reacting the compound of Formula II
20 with an acylating agent; and
(iii) reacting the product of step (ii)
with an aminating agent in an inert solvent to provide
a compound of Formula I; and
(iv) isolating the compound of Formula I
25 or a pharmaceutically acceptable acid addition salt
thereof.

30 This invention provides a process by which
an N-oxide of Formula II can be aminated without the
use of the high pressure conditions used in previous
syntheses of imidazo[4,5-c]quinolin-4-amines, and
without isolation of an intermediate. The process of
this invention is therefore more convenient than the
previous syntheses. Moreover, yield and purity of the
product of Formula I is improved by the process of
35 this invention.


DETAILED DESCRIPTION OF THE INVENTION

40 For the purpose of the instant specification
and claims, the term "lower" when used in connection
with "alkyl" or "alkoxy" designates straight chain or
branched chain groups containing 1 to about 4 carbon
atoms.

The process of this invention is illustrated in the Reaction Scheme below, wherein R, n, R₁, and R₂ are as defined above.

5

Reaction Scheme



10 The Reaction Scheme begins with a 4-hydroxyquinoline of Formula III. Many 4-hydroxyquinolines of Formula III are commercially available. The others are known and/or can be prepared readily by those skilled in the art. Step 1 involves nitration of a

15 4-hydroxyquinoline to provide a 3-nitro-4-hydroxyquinoline of Formula IV. Conventional conditions for such reactions are well known.

Preferred conditions in the instance where n is zero, which afford a product of Formula IV in superior yield compared with conditions used in the prior art, involve heating at about 125°C-130°C in propionic acid in the presence of nitric acid. Preferred conditions in other instances will depend upon the particular 4-hydroxyquinoline used in step 1, and those skilled in the art will be able to select suitable conditions.

In step 2, a 3-nitro-4-hydroxyquinoline is chlorinated at the 4-position to provide a 3-nitro-4-chloroquinoline of Formula V. Some compounds of Formula V are known and disclosed, e.g., in U.S. Pat. No. 3,700,674 (Diehl et al.) and references cited therein, and U.S. Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 2. Step 2 can be carried out by reacting a compound of Formula IV in an inert solvent (e.g., methylene chloride) with a chlorinating agent (e.g., phosphorus oxychloride). Preferred conditions involve chlorination in methylene chloride with a Vilsmeier reagent prepared from thionyl chloride and N,N-dimethylformamide. In such a reaction, the compound of Formula IV is suspended in methylene chloride, and a slight molar excess of thionyl chloride and N,N-dimethylformamide is added to the suspension. Heating to reflux facilitates the chlorination.

Step 3 involves reacting a compound of Formula V in an inert solvent with an amine of the formula R_1NH_2 to provide a compound of Formula VI. Some compounds of Formula VI are disclosed in U.S. Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 3. The reaction of step 3 is preferably carried out in the presence of a tertiary amine catalyst (such as triethylamine), and it is preferred to run the reaction without isolation of the chloro compound from step 2.

Step 4 involves: (i) reduction of the nitro group of the compound of Formula VI; (ii) reaction of the resulting 3-amino compound with a carboxylic acid or an equivalent thereof in order to provide a

cyclized imidazo[4,5-c]quinoline; and (iii) oxidizing the quinoline nitrogen to provide the N-oxide of Formula II. Some compounds of Formula II are disclosed in U.S. Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 4.

5

The reduction in step (4) is preferably carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon. The reduction can be carried out conveniently on a Paar apparatus in an inert solvent such as toluene, ethyl acetate, or a lower alkanol. In part (ii) of step 4, a 3-amino compound is reacted with (a) a 1,1-dialkoxyalkyl alkanoate such as diethoxymethyl acetate, or (b) a carboxylic acid that will introduce the desired R₂ group, or (c) a trialkyl ortho ester of the formula R₂C(Oalkyl)₃, wherein "alkyl" is an alkyl group containing 1 to about 4 carbon atoms, or (d) a combination of such a carboxylic acid with such a trialkyl ortho ester to provide an imidazo[4,5-c]quinoline. The reaction can be carried out by heating, e.g., at about 130°C, in the presence of an acid, preferably an alkanoic acid having one more carbon atom than R₂.

10

15

20

23

30

35

40

Part (iii) of step (4) provides an intermediate of Formula II. The quinoline nitrogen is oxidized with a conventional oxidizing agent that is capable of forming N-oxides. Preferred oxidizing agents include peroxyacids (such as peroxyacetic acid) and hydrogen peroxide. Preferred conditions involve mild heating (e.g., at about 50°C-60°C) in an ethanolic solution of peroxyacetic acid.

A 1H-imidazo[4,5-c]quinolin-4-amine is prepared in step (5) of the Reaction Scheme. Step (5) involves (i) reacting a compound of Formula II with an acylating agent; (ii) reacting the product with an aminating agent; and (iii) isolating the compound of Formula I. Part (i) of step (5) involves reacting an N-oxide with an acylating agent. Suitable acylating agents include alkyl- or aryl- sulfonyl chlorides (e.g., benzenesulfonyl chloride, methanesulfonyl

chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred. p-Toluenesulfonyl chloride is most preferred. Part (ii) of step (5) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, and ammonium phosphate). Ammonium hydroxide is preferred. The reaction of step (5) is preferably carried out by dissolving the N-oxide from Formula II in an inert solvent such as methylene chloride, adding the aminating agent to the solution, and then adding the acylating agent. Preferred conditions involve cooling to about 0°C to about 5°C during the addition of the acylating agent. Heating or cooling can be used to control the rate of the reaction. The product compound of Formula I can be isolated by the conventional means disclosed in U.S. Pat. No. 4,689,338 (Gerster), such as, for example, removal of the solvent and recrystallization from an appropriate solvent (e.g., N,N-dimethylformamide) or solvent mixture, or by dissolution in an appropriate solvent (e.g., methanol) and re-precipitation by addition of a second solvent in which the compound is insoluble.

The compounds of Formula I can be used in the form of acid addition salts such as hydrochlorides, dihydrogen sulfates, trihydrogen phosphates, hydrogen nitrates, methane sulfonates and salts of other pharmaceutically acceptable acids. Pharmaceutically acceptable acid-addition salts of compounds of Formula I are generally prepared by reaction of the respective compound with an equimolar amount of a relatively strong acid, preferably an inorganic acid such as hydrochloric, sulfuric or phosphoric acid or an organic acid such as methanesulfonic acid in a polar solvent. Isolation of the salt is facilitated by the addition of a solvent in which the salt is insoluble (e.g., diethyl ether).

5 The 1H-imidazo[4,5-c]quinolin-4-amines prepared by the process of this invention are disclosed in U.S. Pat. Nos. 4,689,338 (Gerster) and 4,929,624 (Gerster et al.) as antiviral agents. The process as described above is illustrated in the Example below for the synthesis of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. The process affords the final product in a 40% overall yield from 4-hydroxyquinoline.

10 In the following Example, all reactions were run with stirring under an atmosphere of dry nitrogen unless otherwise indicated. The particular materials and amounts thereof recited in the Example, as well as other conditions and details, should not be construed 15 to unduly limit the invention.

EXAMPLE

20 The preparation of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine.

Part A

25 4-Hydroxyquinoline (26.2 g, 0.18 mol) was added to propionic acid (250 mL) and the solution was heated to about 125°C. Nitric acid (16.0 mL of a 70 percent aqueous solution, 0.36 mol) was added dropwise with stirring. When the addition was complete, the mixture was stirred at about 125°C for 10 minutes, then allowed to cool to room temperature. The mixture 30 was diluted with ethanol. The precipitated solid was filtered, washed sequentially with ethanol, water, and ethanol, and dried to afford 3-nitro-4-hydroxyquinoline (27.7 g, 86%) as a light yellow powder.

35

Part B

40 The compound 3-nitro-4-hydroxyquinoline (19.0 g, 0.10 mol) was suspended in dichloromethane (200 mL). Thionyl chloride (8.1 mL, 0.11 mol) and N,N-dimethylformamide (8.5 mL, 0.11 mol) were added.

The reaction mixture was then heated for 3.5 hours at reflux, during which time a small amount of solid precipitated. The reaction mixture was then cooled to -15°C and a solution of isobutylamine (15.1 mL, 0.15 mol), and triethylamine (20.9 mL, 0.15 mol) in dichloromethane (100 mL) was added in a slow stream with vigorous swirling. During the addition the temperature of the reaction mixture rose to 20°C. The resulting solution was heated at reflux for 30 minutes, cooled, and the solvent was removed at reduced pressure to afford a yellow solid product. The product was slurried in water, filtered, washed with water, and dried partially. The partially dried product was then slurried in ethanol (75 mL), filtered, washed successively with a small amount of ethanol and a small amount of diethyl ether, and dried at reduced pressure to afford a yellow crystalline solid product. A second crop of product was obtained by evaporating the ethanol filtrate. The total amount of N-(2-methylpropyl)-3-nitro-4-quinolinamine was 23.3 g.

Part C

N-(2-methylpropyl)-3-nitro-4-quinolinamine (61.3 g, 0.25 mol) was placed in a Paar apparatus along with 5% Pt/C (1.5 g), magnesium sulfate (60 g), ethyl acetate (750 mL), and formic acid (400 mL). The mixture was placed under a hydrogen atmosphere (about 50 psi) and hydrogenated. The catalyst was removed by filtration and the solvent was evaporated to afford the crude product. The crude product was dissolved in 98% formic acid (400 mL) and refluxed for 1 hour. The resulting solution was evaporated to dryness and the resulting solid was dissolved in ethanol (400 mL). Peroxyacetic acid (63 mL of an acetic acid solution containing 32% peroxyacetic acid based on the total weight of the solution, 0.3 mol) was added and the solution was heated at 56°C for about 0.5 hour. The solution was then cooled and the solvents were removed at reduced pressure. The residue was then


co-evaporated with heptane (3x300 mL) to afford a solid. The solid was dissolved in dichloromethane (550 mL) in a Hirsch flask and ammonium hydroxide (125 mL of an aqueous solution containing 28% ammonia by weight based on the total weight of the solution) was added. The resulting mixture was cooled to 0°C and a solution of p-toluenesulfonyl chloride in dichloromethane (52.4 g, 0.275 mol, in 125 mL dichloromethane) was added dropwise over 20 min. The temperature was maintained in the range of 0°C to about 5°C during the addition. After the addition, the reaction mixture was stirred at room temperature for 2 hours. The precipitate was filtered, slurried in ethanol, filtered again, and washed sequentially with ethanol and ether to afford solid 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (45.6 g, 76% crude yield). A 10 g sample of the crude product was dissolved in concentrated hydrochloric acid (25 mL) and the solution was treated with sodium dithionite (3.3 g). The solution was then heated in a steam bath for 15 minutes and diluted with water (75 mL). The product precipitated and was filtered. The solid was then dissolved in a minimum amount of methanol and precipitated by addition of a solution of potassium hydroxide in methanol. The precipitate was filtered and washed with methanol to afford 6.6 g (50% purified yield) of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine with melting point and spectral properties identical to those of an authentic sample.

I claim:

1. A process for preparing a compound of the formula:

5

10



wherein


15 R_1 is straight chain or branched chain alkyl of one to about 10 carbon atoms; straight chain or branched chain alkenyl of 3 to about 10 carbon atoms wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the
20 1-nitrogen; substituted straight chain or branched chain alkenyl of 3 to about 10 carbon atoms wherein the olefinic unsaturation is at least one carbon atom removed from the 1-nitrogen, wherein the substituent is selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, and
25 cycloalkyl of 3 to about 6 carbon atoms substituted by lower alkyl; and substituted straight chain or branched chain alkyl of one to about 10 carbon atoms, wherein the substituent is selected from the group
30 consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, and cycloalkyl of 3 to about 6 carbon atoms substituted by lower alkyl;

35 R_2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms; benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when
40

the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms;

5 each R is independently selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is an integer from zero to 2, with the proviso that if n is 2, then said R groups together contain no more than 6 carbon atoms; or a pharmaceutical acceptable acid addition salt
10 thereof, which process comprises the steps of:

(i) providing a compound of Formula II



25 wherein R , n , R_1 , and R_2 are as defined above:

(ii) reacting the compound of Formula II with an acylating agent; and

30 (iii) reacting the product of step (ii) with an aminating agent in an inert solvent to provide a compound of Formula I; and

(iv) isolating the compound of Formula I or a pharmaceutically acceptable acid addition salt thereof.

35 2. A process according to Claim 1, wherein
the acylating agent is an arylsulfonyl chloride.

3. A process according to Claim 1, wherein the acylating agent is p-toluenesulfonyl chloride.

40 4. A process according to Claim 1, wherein the aminating agent is ammonia or an ammonium salt.

5. A process according to Claim 1, wherein
the aminating agent is ammonium hydroxide.

6. A process according to Claim 1 wherein
5 the compound is 1-(2-methylpropyl)-1H-
imidazo[4,5-c]quinolin-4-amine.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 91/06682

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶According to International Patent Classification (IPC) or to both National Classification and IPC
Int.Cl. 5 C07D471/04; A61K31/47;

//(C07D471/04,235:00,221:00)

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
Int.Cl. 5	C07D

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	EP,A,0 389 302 (RIKER LABORATORIES INC.) 26 September 1990 cited in the application *page4,schemeI;page6,schemeII;page8,schemeIII* & US,A,4 929 624 29 May 1990 ----	1
Y	CHEMICAL ABSTRACTS, vol. 84, no. 21, 24 May 1976, Columbus, Ohio, US; abstract no. 150472, M.A.SOLEKHOVA ET AL: 'Chemistry of heterocyclic N-oxides and related compounds. VI. Reaction of N-oxides of pyridine,bipyridine, and quinoline with ammonia and ammonium salts.' page 533 ; cited in the application & KHIM. GETEROSTSIKL. SOEDIN. no. 2, 1976, pages 229 - 232; ----	1

* Special categories of cited documents :¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

5

24 JANUARY 1992

Date of Mailing of this International Search Report

05 FEB 1992

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

HEYWOOD C.J.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9106682
SA 52611

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 24/01/92

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0389302	26-09-90	US-A-	4929624	29-05-90
		AU-A-	5142690	27-09-90
		CA-A-	2012226	23-09-90
		JP-A-	3027381	05-02-91
		US-A-	5037986	06-08-91
<hr/>				
US-A-4929624	29-05-90	AU-A-	5142690	27-09-90
		CA-A-	2012226	23-09-90
		EP-A-	0389302	26-09-90
		JP-A-	3027381	05-02-91
		US-A-	5037986	06-08-91
<hr/>				